Related Topics News -

     
 Title only   |   Print    Next page > 
     
《大行》瑞銀:中國生科企業上半年銷售大多勝預期 下半年全球研發催化劑成關鍵 首選百濟神州

2026-09-04T  
《大行》大華繼顯:騰訊、信達生物等加入「買入」名單 TMT及IT硬件維持正面看法

2026-09-03T  
美國與百濟神州等九間藥廠達成藥物定價協議

2026-09-01T  
《信而有證》美團季績優異 但高開低走 留意購13007 沽13310

2026-08-31T  
《信而有證》多間內銀、美團、比亞迪齊放榜 建滔獲大股東增持

2026-08-28T  
《信而有證》AI硬件股獲追捧 中際旭創入通彈高半成 智譜急升7% 淡友出手?

2026-08-27T  
《港股》恆指開升121點 百度漲逾3% MiniMax績後高開5%

2026-08-27T  
《藍籌》百濟神州中期淨利潤4.64億美元升385.8% ADR盤前升0.7%

2026-08-26T  
《信而有證》生物醫藥股早段普遍造好 捕捉生科板塊機遇 留意全新上市華夏恆生生科認購證16698/16696

2026-08-26T  
《大行》高盛:百濟神州次季銷售略勝預期 維持「買入」評級

2026-08-24T  
  Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.